Myriad Genetics delivered fourth quarter 2025 revenue of 209800000 with stable year-over-year performance, a GAAP net loss of 7900000, and adjusted EPS of 0.04. Test volumes increased 2% year-over-year, driven by growth in hereditary cancer and mental health testing, while gross margin remained at 70.0%.

Myriad Genetics reported first quarter 2025 revenue of $196 million, a 3% year-over-year decline, primarily due to reduced coverage of GeneSight. Despite this, the company achieved a gross margin of 69% and a GAAP net loss of $0.1 million, benefiting from a significant tax benefit. The company updated its full-year 2025 financial guidance, lowering revenue expectations.

Myriad Genetics reported a 7% year-over-year increase in Q4 2024 revenue, driven by growth in Pharmacogenomics and Prenatal testing. The company's GAAP gross margin improved, and while a GAAP net loss was reported, adjusted EBITDA remained positive. They also reiterated their 2025 financial guidance and entered into a strategic collaboration with PATHOMIQ.

Myriad Genetics reported an 11% increase in revenue to $213 million for the third quarter of 2024, driven by strong performance in pharmacogenomics and prenatal testing. The company's GAAP net loss improved significantly, and adjusted EBITDA increased substantially. Updated financial guidance anticipates full-year revenue between $837 - $843 million and adjusted EPS in the range of $0.12 - $0.14.

Myriad Genetics reported a strong second quarter in 2024 with a 15% year-over-year increase in revenue, driven by growth in Prenatal, Pharmacogenomics, and Hereditary Cancer segments. The company has raised its full-year revenue guidance to $835 - $845 million and adjusted EPS to $0.08 - $0.12.

Myriad Genetics reported a strong first quarter in 2024, achieving a 12% year-over-year revenue growth, driven by growth in Prenatal, Pharmacogenomics, and Hereditary Cancer segments. The company significantly improved its net loss and generated positive adjusted EBITDA.

Myriad Genetics reported an 11% year-over-year increase in both fourth-quarter and full-year revenue, achieving $197 million and $753 million, respectively. The company delivered GAAP EPS of $(0.36) and adjusted EPS of $0.04 for the quarter. Looking ahead, Myriad is raising its 2024 revenue guidance to $820 - $840 million and introducing adjusted EPS guidance of $0.00 - $0.05.

Myriad Genetics reported a 23% increase in third-quarter revenue to $191.9 million, driven by strong growth in testing volumes. The company raised its 2023 revenue guidance and introduced 2024 revenue guidance, reflecting confidence in its growth trajectory.

Myriad Genetics reported a 2% year-over-year revenue growth, inclusive of a $11.7 million change of estimate in the second quarter of 2022 versus an immaterial amount in the current quarter. Excluding these change of estimates, second quarter 2023 revenue increased 10% year-over-year, the third consecutive quarter of double-digit revenue growth. The company's testing volume grew 17% year-over-year, excluding contributions from the SneakPeek® Early Gender DNA Test.

Myriad Genetics reported a strong start to 2023 with a 10% year-over-year revenue increase in Q1, driven by growth in Oncology, Women's Health, and Mental Health businesses. The company is confident in achieving profitability by Q4 2023 and sustainable 10%+ annual organic growth as it enters 2024.

Myriad Genetics reported a strong fourth quarter, with revenue reaching $177.8 million, an 11% increase year-over-year. This growth was driven by a 16% increase in hereditary cancer volumes and a 23% increase in GeneSight® volumes. The company's gross margin for the quarter was approximately 70%.

Myriad Genetics' third quarter revenue was $156.4 million. GAAP EPS was $(0.43) and adjusted EPS was $(0.19). The company acquired Gateway Genomics, LLC for $67.5 million cash and up to an additional $32.5 million of cash consideration.

Myriad Genetics reported revenue of $179.3 million for the quarter ended June 30, 2022, representing a 7% year-over-year increase excluding revenue from divested businesses and a 9% sequential increase from the first quarter of 2022. The company's diluted GAAP EPS was $(0.18) and adjusted EPS was $0.04 in the second quarter of 2022. The company updated its fiscal year 2022 financial guidance to reflect an additional $20 million investment in research and development, technology, and sales and marketing programs. The company ended the quarter with $283.6 million in cash, cash equivalents and investments.

Myriad Genetics reported revenue of $164.9 million for the first quarter of 2022, representing an 11% increase year-over-year excluding revenue from divested businesses. The company's GAAP earnings per share (EPS) improved to $(0.26), and adjusted EPS improved to $(0.03).

Myriad Genetics reported a 4% increase in revenue to $160.8 million in the fourth quarter of 2021. Diluted GAAP EPS was $(0.10) and adjusted EPS was $(0.02). The company ended the quarter with $398.8 million in cash, cash equivalents and investments.

Myriad Genetics reported a 15% year-over-year increase in revenue to $167.3 million for the third quarter of 2021. Excluding revenue from divested businesses, revenue increased 27% year-over-year. Diluted GAAP EPS was $0.30, while adjusted EPS was $(0.02).

Myriad Genetics reported a strong second quarter with revenue growth of 103% year-over-year and earnings exceeding initial expectations. The company is focused on strategic transformation and growth plans, including divestitures and investments in technology and R&D.

Myriad Genetics, Inc. reported financial results for the fiscal fourth-quarter 2020. The company saw a significant recovery in test volume trends throughout the quarter. Total fourth-quarter revenues were $93.2 million and Fourth-Quarter Diluted EPS was ($0.74) and Adjusted EPS of ($0.31).

Myriad Genetics reported a decrease in total revenue by 24% compared to the same quarter last year, with a net loss of $115.2 million and a diluted EPS of ($1.55). The company experienced significant impact from the global pandemic, which led to unprecedented delays in elective testing and negatively impacted all aspects of the business.

Myriad Genetics reported a total revenue of $195.1 million for the second quarter of fiscal year 2020, a 10% decrease compared to the same period last year. The company's diluted EPS was ($0.11), while the adjusted EPS was $0.23.